Charles Schwab Investment Management Inc Adial Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$28.0 - $53.25 $600,404 - $1.14 Million	21,443 New	21,443 $29,000
Q1 2022 May 13, 2022	SELL	$45.0 - $69.0 $522,405 - $801,021	-11,609 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$57.75 - $116.75 $670,419 - $1.36 Million	11,609 New	11,609 $50,000

5.5K

Ticker ADIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,854,000
Market Cap $26M
Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focu...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.